ARCH Venture Management, LLC and affiliated entities filed Amendment No. 3 to Schedule 13D with the SEC on November 13, 2026, reporting beneficial ownership of common stock in Prime Medicine, Inc. as of the triggering event date of November 12, 2026.
Key Highlights
- Shared beneficial ownership: Each ARCH entity reported shared voting and dispositive power over 18,486,894 shares of Prime Medicine common stock.
- Group ownership percentage: The ARCH fund entities each disclosed 8.3% of the class represented by those 18,486,894 shares.
- Robert Nelsen individual holdings: Reporting person Robert Nelsen disclosed sole voting and dispositive power over an additional 155,142 shares, bringing his aggregate beneficial ownership to 18,642,036 shares, or 8.4% of the class.
- Multiple reporting persons: The filing covers eight ARCH entities and at least two named individuals, including Robert Nelsen and Keith Crandell, all organized in Delaware.
- Source of funds: Fund entities listed working capital (WC) or affiliated funds (AF) as the source of funds, according to the filing.
- Triggering event date: The date of the event requiring this amendment was reported as November 12, 2026.
ARCH Venture Group Reports Combined Stake in Prime Medicine Common Stock
According to the filing, ARCH Venture Management, LLC submitted Amendment No. 3 to Schedule 13D on behalf of multiple affiliated reporting persons in connection with their holdings in Prime Medicine, Inc. common stock (par value $0.00001, CUSIP 74168J101). The filing identifies eight ARCH-affiliated entities as reporting persons, including ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Fund XII, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Partners X, LLC, and ARCH Venture Partners XII, LLC, all organized in Delaware.
Each of those eight entities disclosed 0 shares of sole voting or dispositive power, and 18,486,894 shares of shared voting power and shared dispositive power, representing 8.3% of the class, the filing states. Individual reporting person Robert Nelsen reported sole voting and dispositive power over 155,142 shares in addition to the shared 18,486,894 shares, for an aggregate beneficial ownership of 18,642,036 shares, or 8.4% of the class. Keith Crandell was listed separately with shared voting and dispositive power over the same 18,486,894 shares and no sole power, also reflecting 8.3% of the class. A third individual, Kristina Burow, appeared as a reporting person; however, that portion of the filing was cut off in the source text.
The filing is designated as Amendment No. 3, indicating prior filings on the same subject were made by the reporting group. The authorized contact named for notices and communications is Mark McDonnell of ARCH Venture Management, LLC, located at 8755 W. Higgins Road Suite 1025, Chicago, IL 60631, according to the cover page.
What Was Disclosed
ARCH Venture Management and affiliated entities filed Amendment No. 3 to Schedule 13D disclosing aggregate shared beneficial ownership of 18,486,894 shares of Prime Medicine, Inc. common stock, with individual reporting person Robert Nelsen holding an additional 155,142 shares in his sole name, as of November 12, 2026.



Please wait processing your request...